Another interesting option regarding the use of crenolanib in AML patients may be the combination with CAR T-cells, since preclinical analyses revealed a synergistical effect of FLT3 targeting CAR T-cells and crenolanib [93]. The gene discussed is FLT3; the disease is acute myeloid leukemia.